The challenge of developing robust drugs to overcome resistance.

about

Winning the arms race by improving drug discovery against mutating targets.Combatting Drug-Resistant Bacteria with Gyrase and Topoisomerase IV Inhibitors: Patent Highlight.Fused-Ring Oxazolopyrrolopyridopyrimidine Systems with Gram-Negative Activity.

P2860

Q37952291-51C924A4-64AB-4E1E-B947-DC3685EEA955 Q39734986-82A231C3-AF5B-4B20-8F04-83419957854C Q42160840-0BE1A35D-5985-4B7E-AF65-B7B12C063697

P2860

The challenge of developing robust drugs to overcome resistance.

Item

http://www.wikidata.org/entity/Q43221173

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

The challenge of developing robust drugs to overcome resistance.

@en

The challenge of developing robust drugs to overcome resistance.

@nl

type

Item

label

The challenge of developing robust drugs to overcome resistance.

@en

The challenge of developing robust drugs to overcome resistance.

@nl

prefLabel

The challenge of developing robust drugs to overcome resistance.

@en

The challenge of developing robust drugs to overcome resistance.

@nl

P1476

The challenge of developing robust drugs to overcome resistance.

@en

P2093

Amy C Anderson

http://www.w3.org/2001/XMLSchema#string

Celia A Schiffer

http://www.w3.org/2001/XMLSchema#string

Michael P Pollastri

http://www.w3.org/2001/XMLSchema#string

Norton P Peet

http://www.w3.org/2001/XMLSchema#string

P2860

Active human immunodeficiency virus protease is required for viral infectivity

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor

Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands

Design of mutation-resistant HIV protease inhibitors with the substrate envelope hypothesis

Computational design and experimental study of tighter binding peptides to an inactivated mutant of HIV-1 protease

HIV-1 Protease Inhibitors from Inverse Design in the Substrate Envelope Exhibit Subnanomolar Binding to Drug-Resistant Variants

Activation of tyrosine kinases by mutation of the gatekeeper threonine

Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity

P304

755-761

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.DRUDIS.2011.07.001

http://www.w3.org/2001/XMLSchema#string

P433

17-18

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51516493

http://www.w3.org/2001/XMLSchema#string

P698

21784168

http://www.w3.org/2001/XMLSchema#string

P932

3604877

http://www.w3.org/2001/XMLSchema#string

The challenge of developing robust drugs to overcome resistance.

about

P2860

P2860

The challenge of developing robust drugs to overcome resistance.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932